Document Detail

Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade.
MedLine Citation:
PMID:  7897129     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: We examined the time course of ventricular functional improvement in patients with dilated cardiomyopathy who received beta-blockade and the long-term effects of beta-blockade on ventricular mass and geometry in these patients. BACKGROUND: Previous studies have shown that beta-adrenergic blocking agents when administered long term improve ventricular function in patients with heart failure. However, the time course of improvement in ventricular function and the long-term effects of beta-blockade on ventricular mass and geometry are not known. METHODS: Twenty-six men with dilated cardiomyopathy underwent serial echocardiography on days 0 and 1 and months 1 and 3 of either metoprolol (n = 16) or standard therapy (n = 10). At 3 months all patients on standard therapy were crossed over to metoprolol, and late echocardiograms were obtained after 18 +/- 5 (mean +/- SD) months of metoprolol therapy. All echocardiograms were read in blinded manner. RESULTS: Patients treated with metoprolol had an initial decline (day 1 vs. day 0) in ventricular function (increase in end-systolic volume and decrease in ejection fraction). Ventricular function improved between months 1 and 3 (p = 0.013, metoprolol vs. standard therapy). Left ventricular mass regressed at 18 months (333 +/- 85 to 275 +/- 53 g, p = 0.011) but not at 3 months. Left ventricular shape became less spherical and assumed a more normal elliptical shape by 18 months (major/minor axis ratio 1.5 +/- 0.2 to 1.7 +/- 0.2, p = 0.0001). CONCLUSIONS: Patients with heart failure treated with metoprolol do not demonstrate an improvement in systolic performance until after 1 month of therapy and may have a mild reduction in function initially. Long-term therapy with metoprolol results in a reversal of maladaptive remodeling with reduction in left ventricular volumes, regression of left ventricular mass and improved ventricular geometry by 18 months.
S A Hall; C G Cigarroa; L Marcoux; R C Risser; P A Grayburn; E J Eichhorn
Related Documents :
21416259 - Heart failure pharmacogenetics: past, present, and future.
21806529 - Recent trends in australian percutaneous coronary intervention practice: insights from ...
7670649 - Association between various drugs used for hypertension and risk of acute myocardial in...
17804969 - Improved treatment of hospitalized coronary artery disease patients with the get with t...
12681239 - Beta-blockers in chronic heart failure: what have we learned? what do we still need to ...
22461059 - Paradoxical atrial undersensing by a dual chamber pacemaker during atrial fibrillation.
21555309 - High-sensitivity c-reactive protein is a predictor of in-hospital cardiac events in acu...
12382079 - Electrophysiological and antiarrhythmic effects of the novel i(kur) channel blockers, s...
22268109 - Biphasic modulation of the mitochondrial electron transport chain in myocardial ischemi...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  25     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  1995 Apr 
Date Detail:
Created Date:  1995-04-21     Completed Date:  1995-04-21     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1154-61     Citation Subset:  AIM; IM    
Echocardiography Laboratory, Dallas Veterans Administration Hospital, Texas.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Cardiomyopathy, Dilated / drug therapy*,  physiopathology,  ultrasonography
Cross-Over Studies
Double-Blind Method
Hypertrophy, Left Ventricular / drug therapy*,  physiopathology,  ultrasonography
Metoprolol / therapeutic use*
Middle Aged
Observer Variation
Systole / physiology
Time Factors
Ventricular Function, Left / drug effects*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced he...
Next Document:  High prevalence of atrial fibrosis in patients with dilated cardiomyopathy.